v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development, net of grants $ 4,390 $ 4,217
General and administrative, net of grants 2,427 2,340
Total operating expenses, net 6,817 6,557
Loss from operations (6,817) (6,557)
Other income, net 37 255
Net loss $ (6,780) $ (6,302)
Net loss per common share - basic (in dollars per share) $ (0.08) $ (0.11)
Net loss per common share - diluted (in dollars per share) $ (0.08) $ (0.11)
Weighted average common shares outstanding - basic (in shares) 81,269 59,236
Weighted average common shares outstanding - diluted (in shares) 81,269 59,236